中成药首次全国集采已经过去2年，中成药价格虚高的问题解决了吗？ 7月24日，广西药品集团采购服务平台发布《关于开展中成药挂网价格治理工作的通知》，针对169个高 价中成药，给出了"省内最小每日费用"参考，要求药企在7月30日前完成挂网价格调整。 在此之前的7月22日，吉林省发布的通知更为直接，不仅公示了52个价格虚高的中成药，还给出了这些 药物的每日费用与省内最小每日费用的价差倍数。《每日经济新闻》记者注意到，无论从药品种类还是 可比价差看，与同期披露的43个价格虚高的化学药相比，中成药价格虚高的情况更为严重。其中，重庆 希尔安药业有限公司的元胡止痛片的价差倍数达117倍多。 多种中成药因价格虚高被点名，最高价差超百倍 截至目前，吉林、河南、江西、山西、内蒙古、宁夏、河北、江苏等多地密集开展中成药挂网价格治 理，大批中成药被纳入治理范围，安宫牛黄丸、板蓝根颗粒、小柴胡颗粒、六味地黄丸等知名品种均在 列。 而根据吉林省发布的价格虚高未过评（未通过一致性评价）药品名单和价格虚高中成药产品名单，中成 药价格虚高的问题更为突出。 过去9年间，上述多个薄弱环节已被修补。比如，2023年6月，中成药首次全国集采在武汉开标 ...

Core Viewpoint - Guangyuyuan, a "Chinese Time-Honored Brand," is focusing on growth as a fundamental objective, emphasizing the importance of maintaining a competitive edge through strategic product positioning and operational efficiency [7][8][9]. Company Strategy - The company has adopted the "1541" strategic framework to promote growth as a primary goal, launching the "Dragon and Phoenix Big Product" strategy centered around its core products, Gui Ling Ji and Ding Kun Dan [8][9]. - In 2024, Guangyuyuan opened 43 new agents, increasing its total terminal stores to 462, with Gui Ling Ji sales growing over 25% and Ding Kun Dan nearly 10% [8]. Financial Performance - In Q1 2025, Guangyuyuan reported revenue of 417 million yuan, a year-on-year increase of 21.48%, and a net profit of 63.58 million yuan, up 53.94% [8]. Market Outlook - The health policy in China is expected to drive the market for premium traditional Chinese medicine, projected to exceed 300 billion yuan by 2030, aligning with Guangyuyuan's dual attributes of "treatment necessity + consumption upgrade" [9]. Product Development - Guangyuyuan emphasizes the importance of product efficacy, adhering to traditional methods in the production of its medicines, which include strict selection standards for raw materials [11][12]. - The company is also engaged in innovative research and development in collaboration with institutions like the China Academy of Chinese Medical Sciences [12]. Marketing and Growth Strategy - Guangyuyuan is implementing a "Four Feet and Two Wings" marketing strategy to enhance its market position and aims to become a leader in the premium traditional Chinese medicine sector within three years [13][14]. - The company is focusing on a multi-dimensional approach to marketing, including partnerships with top media and consulting firms to enhance brand visibility and market penetration [14][15].

Group 1 - Kanghong Pharmaceutical received a drug registration certificate for Lifisig Eye Drops, approved for treating dry eye symptoms [1] - Kanghong Biotech, a wholly-owned subsidiary, received clinical trial approval for KH813 injection for metastatic non-squamous non-small cell lung cancer [1] - Kanghong Pharmaceutical was established in October 1996, focusing on drug and medical device research, production, and sales [1] Group 2 - Guoyuyuan's subsidiary received a government subsidy of 7.5521 million yuan, accounting for 10.14% of the company's audited net profit for 2024 [2] - Guoyuyuan was founded in November 1996, specializing in drug research, production, and sales [3] Group 3 - Haicheng Bonda's subsidiary signed a lease termination agreement, incurring a termination fee of 3.35 million USD [4] - Haicheng Bonda was established in December 2009, providing comprehensive modern logistics services [4] Group 4 - Hongxin Electronics' subsidiary signed contracts totaling 373 million yuan for computing power business [5] - Hongxin Electronics was founded in September 2003, focusing on FPC research, design, manufacturing, and sales [6] Group 5 - Tianbang Food reached a settlement agreement regarding a 1.214 billion yuan lawsuit, agreeing to repay 410 million yuan over 36 months [8] - Tianbang Food was established in September 1996, specializing in pig farming and pork processing [9] Group 6 - Daoshi Technology's controlling shareholder plans to reduce holdings by up to 1.97% of the company's shares [10] - Daoshi Technology was founded in September 2007, focusing on ceramic color glazes and related products [10] Group 7 - Jinpu Titanium is planning a major asset restructuring, leading to a stock suspension [10] - Jinpu Titanium was established in November 1989, specializing in titanium dioxide production and sales [11] Group 8 - Shenzhen Energy plans to invest 6.332 billion yuan in upgrading the Mawan Power Plant [12] - Shenzhen Energy was founded in August 1993, focusing on conventional and renewable energy development [13] Group 9 - Lihua Co. plans to reduce holdings by up to 3% of the company's shares [14] - Lihua Co. was established in June 1997, specializing in the breeding and sales of poultry [15] Group 10 - China Communications Construction Company plans to repurchase shares worth 500 million to 1 billion yuan [16] - China Communications Construction Company was founded in October 2006, focusing on infrastructure design and construction [17] Group 11 - Huatiankeji's subsidiary received a government subsidy of 80.6569 million yuan, accounting for 13.09% of the company's latest audited net profit [20] - Huatiankeji was established in December 2003, specializing in integrated circuit packaging and testing [21] Group 12 - Luxin Chuangtou plans to acquire shares in Hongke Electronics for a total of 9 million yuan [23] - Luxin Chuangtou was founded in November 1993, focusing on venture capital and industrial development [24] Group 13 - Feilong Co.'s controlling shareholder plans to reduce holdings by up to 563,250 shares [25] - Feilong Co. was established in January 2001, specializing in thermal management components for automotive and civil applications [26] Group 14 - Linglong Tire submitted an application for H-share listing on the Hong Kong Stock Exchange [27] - Linglong Tire was founded in June 1994, focusing on tire design, development, manufacturing, and sales [27] Group 15 - Saiwei Electronics plans to acquire 9.5% of its subsidiary's shares for up to 324 million yuan [28] - Saiwei Electronics was established in May 2008, focusing on MEMS chip development and semiconductor equipment [28] Group 16 - Suzhou Bank's major shareholder plans to increase holdings by no less than 400 million yuan [29] - Suzhou Bank was founded in December 2004, focusing on various banking services [29]

对当期损益的影响：广誉远中药股份有限公司（以下简称"公司"）控股 子公司西藏广誉远药业有限公司收到与收益相关的政府补助，将直接计入损益, 具体的会计处理以及对公司损益的影响最终以审计机构年度审计确认后的结果 为准。 一、获得补助的基本情况 2025 年 6 月 27 日，公司控股子公司西藏广誉远药业有限公司收到与收益相 关的政府补助 7,552,142.00 元，占公司 2024 年度经审计归属于上市公司股东净 利润的 10.14%。 二、补助的类型及其对上市公司的影响 证券代码：600771 证券简称：广誉远 编号：临 2025-013 广誉远中药股份有限公司 关于控股子公司收到政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 获得补助金额：7,552,142.00 元 公司按照《企业会计准则第 16 号——政府补助》的相关规定，确认上述事 项并划分补助的类型，所收到的政府补助与收益相关，将直接计入损益。上述政 府补助未经审计，具体的会计处理以及对公司损益的影响最终以审计机构年度审 计确认后的结 ...

Core Viewpoint - The company emphasizes the necessity for traditional brands to actively embrace transformation rather than relying solely on historical achievements [1][5]. Group 1: Company Strategy and Performance - The company reported total assets of 2.276 billion yuan and achieved operating revenue of 1.221 billion yuan with a net profit attributable to shareholders of 74 million yuan for the year ending December 31, 2024 [3]. - In Q1 2025, the company experienced a strong rebound, with operating revenue reaching 417 million yuan, a year-on-year increase of 21.48%, and a net profit of approximately 63.58 million yuan, up 53.94% year-on-year [3]. - The "1541" strategic framework focuses on building a high-quality traditional Chinese medicine (TCM) industry chain, including five major actions: ensuring raw material supply, production support, marketing transformation, innovative research and development, and digital upgrades [5]. Group 2: Market Challenges and Responses - The company faces challenges such as shrinking market share, profit compression due to medical insurance cost control, intensified competition from traditional channels, and the need for product innovation driven by consumer downgrade [5]. - The company has restructured its channel strategy by enhancing collaboration with top chain enterprises and expanding its network, adding 43 new agents and reaching a total of 462 retail stores in 2024 [5]. Group 3: Cultural and Brand Development - The company is committed to strengthening its cultural foundation and brand value, addressing key questions about its value system and driving forces during the shareholder meeting [6]. - Initiatives include establishing a heritage studio with scholars, conducting educational activities, and launching live broadcasts to enhance brand cultural influence [6]. - The company plans to restore historical sites and apply for recognition of its industrial heritage, aiming to showcase its rich cultural background and create a new historical experience area [6]. Group 4: Long-term Vision - The company is pursuing a long-term strategy to navigate industry cycles, focusing on strategic determination, innovative vitality, and cultural appeal to achieve its goal of becoming a flagship enterprise in TCM [7].

证券代码：600771 证券简称：广誉远 公告编号：2025-012 广誉远中药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 其中，现场出席本次股东大会的股东及股东代表共 13 人，代表股份 74,991,867 股，占公司有表决权股份总数的 15.32%；参加网络投票的股东及股 东代表共 912 人，代表股份 9,734,784 股，占公司有效表决权股份总数的 1.99%。 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，董事长李晓军主持，会议采取现场投票与网络投票 相结合的表决方式。会议的召集、召开及表决方式符合《公司法》、《公司章程》 及其他有关法律、法规的规定。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事6人，出席4人，董事季占璐因公务原因未能亲自出席本次会议； (一)股东大会召开的时间：2025 年 6 月 24 日 (二)股东大会召开的地点：山西省太原市小店区长 ...

北京海润天睿律师事务所 关于广誉远中药股份有限公司 2024 年年度股东大会的法律意见书 致:广誉远中药股份有限公司 北京海润天睿律师事务所(以下简称"本所")接受广誉远中药股份有限公 司(以下简称"公司")的委托,指派冯政律师、陈媛律师出席公司 2024 年年度 股东大会,并依据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》等法律、法 规和规范性文件及《公司章程》的规定,就公司本次股东大会的召集、召开程序、 出席会议人员的资格、召集人资格、表决程序、表决结果等有关事宜出具本法律 意见书。 对本法律意见书的出具,本所律师特作如下声明: 1. 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实,严格履行了法定职责，遵循了勤勉尽责和诚实信用原则, 进行了充分的核查验证,保证本法律意见所认定的事实真实、准确、完整,所发 表的结论性意见合法、准确,不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 2. 本所律师仅就本 ...

Core Viewpoint - GuangYuYuan Chinese Herbal Medicine Co., Ltd. is preparing for its 2024 annual shareholders' meeting, focusing on maintaining shareholder rights and ensuring efficient proceedings [1][2][3]. Meeting Arrangements - The annual shareholders' meeting is scheduled for June 24, 2025, at 14:00 in Taiyuan, Shanxi [3]. - Shareholders must arrive 30 minutes early for registration and are limited to three minutes for speaking [2][3]. - Voting will occur both on-site and through internet platforms during specified time slots [3]. Agenda Items - The meeting will cover several key reports, including the 2024 annual work report from the board of directors, the supervisory board's report, financial statements, profit distribution plans, and independent directors' reports [3][4][5]. Board of Directors' Report - The board held six meetings during the reporting period, addressing various operational and financial matters, including accounting errors and annual reports [6][7]. - The company reported total assets of 2.276 billion and net assets of 1.570 billion as of December 31, 2024, with a revenue of 1.221 billion, a decrease of 4.87% year-on-year [13]. Operational Focus - The company emphasizes growth and operational efficiency, focusing on four core products and expanding its market presence through partnerships and new store openings [13][14]. - A cultural heritage strategy is in place to enhance brand influence, including collaborations with educational institutions and media [14][15]. Quality Assurance - The company is committed to high-quality production standards, implementing a comprehensive quality management system and collaborating with research institutions for innovation [15][16][20]. Governance and Compliance - The company is enhancing its governance structure, focusing on compliance and risk management, and has revised various internal regulations to ensure transparency and accountability [17][22][27]. Future Strategy - The company aims to strengthen its market position by leveraging its historical and cultural assets, enhancing brand visibility, and driving innovation through technology [19][21][22].

广誉远中药 股份有限公 司 GuangYuYuan Chinese Herbal Medicine Co., Ltd. 2024 年年度股东大会 会议资料 二〇二五年六月二十四日 中国·山西·太原 | | | | 一、公司 | 2024 | 年年度股东大会会议须知 3 | | --- | --- | --- | | 二、公司 | 2024 | 年年度股东大会会议议程 4 | | 三、公司董事会 | | 2024 年度工作报告 6 | | 四、公司监事会 | | 年度工作报告 2024 15 | | 五、公司 | 2024 | 年度财务决算报告 18 | | 六、公司 | 2024 | 年度利润分配预案 26 | | 七、公司独立董事 | | 2024 年度述职报告 27 | | 八、公司 | 2024 | 年年度报告及摘要 51 | | 九、公司关于未弥补亏损超过实收股本总额三分之一的议案 52 | | | | 十、公司 | 2024 | 年度计提信用减值损失和资产减值准备的议案 54 | | 十一、关于续聘 | | 2025 年年度财务审计机构暨内部控制审计机构的议案 58 | | 十二、公司关于取消监事会 ...

Core Viewpoint - Guangyuyuan Traditional Chinese Medicine Co., Ltd. plans to cancel its supervisory board and amend its articles of association to enhance corporate governance and comply with the new Company Law [1][2]. Summary by Sections Cancellation of Supervisory Board and Amendments to Articles of Association - The company’s board of directors unanimously approved the proposal to cancel the supervisory board, transferring its powers to the audit committee of the board [1]. - The amendments to the articles of association and related rules include changes to the shareholder meeting rules, board meeting rules, independent director system, and cash dividend management system [1][2]. Details of Amendments - The amendments aim to improve the operational standards of the company and align with the guidelines for listed companies [1]. - Specific changes include the definition of the legal representative, responsibilities of the board, and the rights and obligations of shareholders [2][3][5]. Shareholder Meeting Procedures - The proposal requires approval from the shareholders' meeting, and until then, the current supervisory board will continue its duties [2]. - The revised articles will enhance the clarity of shareholder rights and the procedures for convening meetings [2][10]. Financial and Operational Governance - The amendments also address the management of financial assistance and the conditions under which the company can provide guarantees [5][23]. - The company will ensure that any financial assistance provided does not exceed 10% of the total issued share capital [5][23]. Compliance and Legal Framework - The company emphasizes adherence to legal requirements and the importance of transparency in its operations [1][10]. - The amendments include provisions for the handling of disputes regarding the validity of board and shareholder resolutions [10][11].